



OPEN ACCESS

The Progress of Next Generation Sequencing in the Assessment of Myeloid Malignancies

Fulya Öz Puyan¹, Serhan Alkan²

¹Department of Pathology, Trakya University School of Medicine, Edirne, Turkey

²Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, California, USA

The introduction and advances on next-generation sequencing have led to novel ways to integrate simultaneous assessment of multiple target genes in routine laboratory analysis. Assessment of myeloid neoplasms with targeted next-generation sequencing panels shows evidence to improve diagnosis, assist therapeutic decisions, provide better information about prognosis, and better detection of minimal residual disease. Herein, we provide information for application and

utilization of next-generation sequencing studies with a focus on the most important mutations in acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative neoplasms, and other myelodysplastic/myeloproliferative neoplasms in order to integrate them into the daily clinical practice.

Keywords: Myeloid neoplasia, next-generation sequencing, somatic mutation

Next-generation sequencing (NGS) technology can be of great utility in the clinical assessment of various neoplasms. NGS can be rapidly integrated into the diagnostic laboratories and merged into current clinical practice. However, bioinformatics and genetic code technology and language are difficult to understand for practitioners who are not familiar with molecular biology. We will review the recent developments in NGS, technical progress, and focus on the approach of diseases affecting the myeloid lineage, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myeloproliferative diseases (CMPDs) such as polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), atypical CMPD, chronic myelomonocytic leukemia (CMML) and chronic eosinophilic leukemia (CEL) and mast cell disease.

Due to the increasing number of mutations that are necessary for diagnosis, it is becoming impractical to do a single gene testing analysis. Furthermore, multigene assessment is providing guidance for determining prognosis in many diseases. Since many of the diseases encountered in clinical practice show more than one molecular abnormality, we could adapt NGS based assays to have simultaneous detection of multiple somatic mutations in tens or hundreds of target genes that are associated with specific diseases. NGS assays are becoming cheaper, faster, and rapidly adopted by many laboratories and since there is an increasing number of actionable targets that could benefit from these assays. However, NGS technology requires highly complex bioinformatics and

laboratory technology to develop a diagnostic pipeline. Currently, there are two commonly used NGS. Sequencing differs in these technologies but they use similar bioinformatics principles for determining abnormal sequences that are not matching reference sequences.

There are also three different enrichment methods used for NGS sequencing: Hybrid capture, Amplicons, and Anchored Multiplex polymerase chain reaction (1). However, until now there is no single database available for clinical annotations to determine the significance of variants. Moreover, these assays are expensive and reimbursement remains low.

The introduction of NGS into clinical laboratories has significantly changed the use of molecular techniques. Testing for multiple genes in a panel using NGS platforms is more practical and economical (2,3). Furthermore, the cost of adding a new gene to the panel is relatively inexpensive, in comparison to performing multiple single-gene tests. The presence of specific genetic mutations could aid clinicians in 4 ways: 1) diagnostic algorithms, 2) prognosis assessment, 3) use of targeted therapy, and 4) monitoring treatment response and residual disease. Despite increased utilization, NGS assays remain challenging particularly for the identifications of variants without a known clinical significance. To address these concerns, new terms in NGS reports have been adopted: "actionable", "potentially actionable", "Variant of Undetermined Significance", "likely benign" or "benign".

Address for Correspondence: Fulya Öz Puyan - Serhan Alkan, Department of Pathology, Trakya University School of Medicine, Edirne, Turkey - Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, California, USA
e-mail: fulyaozpuyan@trakya.edu.tr - Serhan.Alkan@cshs.org ORCID: orcid.org/0000-0002-4483-2576 - orcid.org/0000-0002-4483-2576

Received: 18 July 2018 Accepted: 24 September 2018 • DOI: 10.4274/balkanmedj.galenos.2018.2018.1195



Available at www.balkanmedicaljournal.org

Cite this article as:

Öz Puyan F, Alkan S. The Progress of Next Generation Sequencing in the Assessment of Myeloid Malignancies. Balkan Med J 2019;36:78-87

©Copyright 2019 by Trakya University Faculty of Medicine / The Balkan Medical Journal published by Galenos Publishing House.

Mutation profiles in acute myeloid leukemia

The Cancer Genome Atlas Network has many studies that report recurrent mutations and show a complex network of genetic mutations (4,5). Despite these exhaustive studies, there is no gene-specific diagnostic entity. However, there are some mutations leading to an aberrant activation of proteins that have a crucial effect on hematopoietic progenitor cell proliferation and differentiation. The mutations in AML involve epigenetic modifiers (*TET2*, *IDH1/IDH2*, *DNMT3A*, *ASXL1*, *KMT2A*, *EZH2*), activated signaling pathway (*FLT3*, *KRAS*, *NRAS*, *KIT*), tumor suppressor genes (*TP53*, *WT1*), RNA splicing (*SF3B1*), nucleophosmin mutation (*NPM1*), and genes coding for transcription-differentiation (*CEBPA*, *RUNX1*) (Figure 1) (6-8). Recurrently mutated genes in AML and MDS are listed in Table 1.

Recent studies have demonstrated that genes mutated in AML with a normal karyotype AML (NK-AML) share significant overlap with genes mutated in MDS (9,10). The World Health Organization (WHO) 2016 classification recognizes AML with mutated *NPM1* and AML with bi-allelic mutation of *CEBPA* as specific to AML classification categories and AML with mutated *RUNX1* as a provisional entity (8-10). The most frequently mutated genes in NK-AML occur in the following genes: nucleophosmin (*NPM1*), Fms-related tyrosine kinase 3 (*FLT3*) and DNA methyltransferase 3A (*DNMT3A*), Ten-eleven translocation-2 (*TET2*), isocitrate dehydrogenase 1 and 2 (*IDH1* and *IDH2*), CCAAT/enhancer binding protein alpha (*CEBPA*), *NRAS*, Additional sex comb-like 1 (*ASXL1*), *WT1* and runt-related transcription factor-1 (*RUNX1*). Mutations of *FLT3*, *DNMT3A*, and *NPM1* are often present concurrently, while other mutations of *NPM1*, *RUNX1*, *CEBPA*, and *TP53* are almost always mutually exclusive both at diagnosis and during disease transformation (11-19).

The WHO classification of AML includes many specific chromosomal abnormalities determined by karyotyping (11). The gene mutations recognized as specific entities by the 2016 WHO classification include *NPM1*, *CEBPA*, and *RUNX1* mutations. However, since the publication of this classification, it became very important to clinically recognize other pathogenic variants such as those involving *FLT3* (*ITD* and *TKD*) and *IDH1/2*. This can drastically change the clinical management of AML patients since the US Food and Drug Administration (FDA) has approved specific inhibitors for *FLT3* and *IDH2* positive AML (20,21).

The gene *NPM1* is the most frequently mutated gene in the adult type AML. It occurs approximately in 50 to 60% of cytogenetically normal AMLs and in 2 to 5% of MDS cases. It is often characterized by CD34 antigen negativity with a bright expression of CD33 and monocytic differentiation. *NPM1* mutations include small insertions (4-11bp in size), resulting in an aberrant cytoplasmic localization of the mutant protein nucleophosmin which can be detected immunohistochemically (21,22). *NPM1* mutations increase disease-free and overall survival in patients with AML. Secondary mutations [*FLT3-ITD*, *DNMT3A* (21), *IDH*, *TET2* mutations] are frequently accompanying these patients. *FLT3-ITD* mutations are observed in 40% of *NPM1* mutated AML patients. In general, *FLT3 ITD* positive patients without other molecular abnormalities show poor clinical outcome while *NPM1* positive patients have a better clinical response. Coexistence of *FLT3-ITD* mutation in *NPM1* positive patients is associated with a poor prognosis in young AML patients compared with patients with *NPM1^{mut}*/*FLT3^{wild}* type (4,11,17,23).

Among transcription factor mutations in myeloid neoplasia, *CEBPA* and *RUX1* mutations are deemed important by the WHO due to their prognostic implications. CCAAT Enhancer Binding Protein-alpha (*CEBPA*)




FIG. 1. The most frequent gene mutations and cellular pathways in acute myeloid leukemia.

is a transcription factor responsible for promoting granulocytic maturation in regulating cellular function. *CEBPA* mutations are observed in approximately 10% of *de novo* AML patients and are commonly bi-allelic. The bi-allelic mutation is a favorable prognostic marker. Germline mutations of *CEBPA* predispose to the development of AML in young patients. The concurrence of *FLT3-ITD* mutation is an adverse prognostic finding in *CEBPA* mutated-AML patients (23). *RUNX1* encodes the DNA binding alpha subunit of the core binding factor (*CBFalpha*) that is involved in

the normal differentiation of hematopoietic cells. *RUNX1* has also tumor suppressor properties and loss of function of the gene that contributes to tumorigenesis in myeloid cancers. *De novo* AML with mutated *RUNX1* in the absence of MDS related cytogenetic abnormalities appears to be a distinct entity with adverse outcome. *RUNX1* mutations are detected in approximately 4% to 16% of AML and 9% of MDS (11). They are commonly seen in older patients with NK-AML and MDS-associated AML. In several multivariate analyses, they have been associated with worse overall survival (23-25).

TABLE 1. Common gene mutations in AML, MDS, and their clinical significance

Gene	Locus	Functional classification	Approx. frequency in NK-AML %	Approx. frequency in MDS %	Effect on prognosis	Clinical significance
<i>NPM1</i>	5q35.1	Nucleophosmin mutation	50-60	2-5	Good	CD34 ⁻ blasts with cuplike nuclear invaginations, immunohistochemically detectable, favorable prognostic marker, co-occurrence with <i>FLT3-ITD</i> , <i>DNMT3A</i> , <i>IDH</i> , <i>TET2</i> mutations
<i>FLT3-ITD</i>	13q12.2	Signal transduction	20-30	2-6	Poor	Unfavorable prognostic marker, <i>NPM1</i> ⁺ / <i>FLT3</i> ⁺ mutations occur early in MDS (risk of rapid progression to AML), usage of <i>FLT3</i> inhibitors
<i>CEBPA</i>	19q13.11	Transcription factor mutation	10-18	<2	Good	The bi-allelic mutation has a favorable prognosis, co-occurrence with <i>FLT3-ITD</i> adverse effect
<i>RUNX1</i>	21q22.12	Transcription factor mutation	4-16	9	Poor	Tumor suppressor properties, a provisional entity in 2016 WHO classification, germline mutation associated with familial platelet disorder, unfavorable prognostic marker
<i>RAS</i>	12p12.1 (KRAS) 1p13.2 (NRAS)	Signal transduction	rare	5-10	None	Acquisition of RAS mutation on MDS patient is associated with leukemic transformation
<i>KIT</i>	4q12	Signal transduction	6	<2	Poor	Mostly found in CBF-AML and AML with t(8;21), the presence of a <i>KIT</i> mutation in CBF-AML worsens prognosis, usage of <i>KIT</i> inhibitors
<i>DNMT3A</i>	2p23	DNA methylation	20	2-8	Poor	Co-occurrence with <i>FLT3</i> , <i>NPM1</i> , <i>IDH1</i> mutations. Associated with CHIP, CCUS. An early event in leukemogenesis. Frequency increases with age
<i>TET2</i>	4q24	DNA methylation	10-15	10-25	Unclear-Poor	Co-occurrence with <i>NPM1</i> , <i>IDH1</i> mutations. Associated with CHIP, CCUS. An early event in leukemogenesis. More frequent in CMML. Frequency increases with age
<i>IDH</i>	2q34 (IDH1) 15q26.1 (IDH2)	DNA methylation	15-25	2-12	Unclear	Co-mutated with <i>TET2</i> and <i>WT1</i> mutations. Usage of IDH2 inhibitor and IDH1 inhibitor in clinical development
<i>ASXL1</i>	20q11	Chromatin-Histone modification	6-10	14-22	Poor	Early genetic event. More frequent in CMML and PMF. Associated with CHIP
<i>EZH2</i>	7q35-7q36	Chromatin-Histone modification	2	6-12	Poor	Loss of function mutations more common in secondary AML
<i>TP53</i>	17p13.1	Tumor suppressor-DNA repair	5-18	7-12	Poor	Associated with complex karyotype, resistance to chemotherapy
<i>SF3B1</i>	2q33.1	RNA splicing	<3	20-30	Good	More frequent in MDS with RS. RARS-T with the <i>SF3B1</i> mutation is regarded as MDS/MPN-RS-T in 2016 WHO classification, associated with CHIP
<i>SRSF2</i>	17q25.1	RNA splicing	<8	10-15	Unclear-Poor	More frequent in CMML

AML: acute myeloid leukemia; CBF-AML: Core binding factor-acute myeloid leukemia; CCUS: clonal cytopenia of undetermined significance; CHIP: clonal hematopoiesis of indeterminate potential; CMML: chronic myelomonocytic leukemia; MD: myelodysplastic; MDS: myelodysplastic syndrome; MPN: myeloproliferative neoplasm; NK: normal karyotype; PMF: primary myelofibrosis; RS-T: ring sideroblasts and thrombocytosis; WHO: World Health Organization

FLT3 is a class III receptor tyrosine kinase coding for signal transduction gene. This receptor is important for proliferation and differentiation of hematopoietic stem cells. Its expression is downregulated during differentiation. *FLT3* mutations occur in 30% to 40% of AML patients with normal cytogenetics and 2% to 6% of MDS cases. Two types of mutations are observed in *FLT3* gene: *FLT3-ITD* (*internal tandem duplications*) mutations (with a frequency of 75% to 80%) and *FLT3-TKD* (*tyrosine kinase domain*) (with a frequency of 20% to 25%). *FLT3* mutated patients show higher white blood cell count, loss of HLA-DR and CD34 antigen negativity, and impaired survival (26). AML patients with *FLT3-ITD* mutation appear to benefit from allogeneic stem cell transplantation. However, the prognostic effect of *FLT3-TKD* remains controversial (27). In 2017, the FDA approved treatment with midostaurin for newly diagnosed patients with *FLT3*-mutated AML due to the observation of a significant beneficial outcome (28,29). In MDS, *FLT3* mutations are observed in high-risk subgroups and are associated with complex karyotype (30,31). *NPM1* and *FLT3* mutations are found primarily in AML; however, the presence of these mutations in an MDS patient should alert the clinician about the risk of rapid progression to AML (22). Alterations on *FLT3* signaling pathway seems to be the most important prognostic factor for overall survival in AML patients younger than 60 years.

The other signal transduction genes are *KIT* mutations that are frequent in gastrointestinal stromal tumors, germ cell tumors, melanomas, and systemic mast cell diseases. They can be detected in approximately 6% of patients with newly diagnosed AML and 20% of AML patients with t(8;21) *RUNX1-RUNXT1* and 30% of AML patients with inv(16) or t(16;16) *CBFB-MYH11* (the core binding factor AMLs-CBF-AML). *KIT* mutation in AML increases the risk of relapse and worsens the good prognosis of CBF-AML (32-36).

There are a number of other genes playing a role in the pathogenesis of AML and appear to be important for overall survival despite not being recognized as specific entities. DNA methylation mutations and chromatin/histone modifications belong to epigenetic modifiers. *DNMT3A* encodes an epigenetic regulator and mediates *de novo* methylation of CpG dinucleotides and are seen in approximately 20% of AML patients with normal karyotype. This mutation tends to shorten overall survival (14,37). *TET2* is also involved in the epigenetic regulation of DNA methylation. *TET2* mutations occur in approximately 10% to 15% of AMLs. As *TET2* is a key regulator in hematopoietic stem cell renewal and differentiation, their mutations result in increased stem cell renewal and myeloid hyperplasia with impaired differentiation. These tend to have a poorer prognosis in NK-AML. *TET2* mutations predict the response to hypomethylating agents (4,38).

IDH1/IDH2 mutations prevent the conversion of isocitrate to alpha-ketoglutarate in the Krebs cycle; create an oncometabolite that inhibits the function of *TET2*. *IDH1/IDH2* mutations often mutate with *TET2* and *WT1* mutations (39). Between 15% to 25% of AML and approximately 2% to 12% of MDS cases display *IDH* mutations (40). The prognostic significance of *IDH* mutations in AML is currently unclear. *IDH2* inhibitor had been successful in the management of *IDH2* positive AML patients while *IDH1*

inhibitor is showing promising results in ongoing clinical trials (4,20,34,40).

Chromatin/Histone Modification mutations such as Additional Sex Combs Like Transcriptional Regulator 1 (*ASXL1*) mutations and Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit (*EZH2*) mutations are a part of the epigenetic modifiers. *ASXL1* gene is involved in the epigenetic regulation of gene expression. They are uncommon in *de novo* AML (6.5%), but more frequent in AML arising from a prior myeloid neoplasm (up to 30%) (41-43). These mutations are associated with shorter overall survival and resistance to chemotherapy. *KMT2A: lysine(K)-specific methyltransferase 2A* (*KMT2A/MLL*) gene plays a role in hematopoiesis and cell differentiation. *KMT2A* mutations co-occur with an additional gene mutation (*IDH2/DNMT3A/U2AF1/TET2*). This mutation is frequently associated with trisomy 11 (90%) and a poorer prognosis (17,44,45).

TP53 protein is a transcription factor and tumor suppressor gene that determines whether the cell undergoes repair, senescence or apoptosis. Although somatic *TP53* mutations are frequently seen in 50% of solid tumors, they are uncommon in *de novo* AML (5% to 18%) and they are associated with secondary or therapy-related AMLs. *TP53* mutations often coexist with complex karyotypes, chemotherapy resistance, and reduced overall survival compared with *TP53^{wild}* AML patients. *TP53^{mut}* AML patients have also high relapse rates after stem cell transplantation (46-48). Despite these findings, a recent study indicated that AML patients with cytogenetic abnormalities associated with unfavorable risk, *TP53* mutations, or both had a favorable clinical response to decitabine (49,50).

Figure 2 represents these risk categories associated with distinct molecular mutations that should be screened by NGS in AML patients.

For the monitoring of minimal residual disease (MRD) in AML; NGS based technologies can be used besides multiparameter flow cytometry (MFC). MFC is a more reliable method for monitoring remission than conventional morphology-based assessment in AML patients; however, MFC lacks sensitivity for detecting




FIG. 2. AML risk categories and associated molecular abnormalities.
(*FLT3-ITD*^{low}: *FLT3-ITD/wild type* allelic ratio <0.5; *FLT3-ITD*^{high}: *FLT3-ITD/wild type* allelic ratio >0.5)
AML: acute myeloid leukemia

residual disease. Therefore, a combined result of sequencing and flow cytometry detects residual disease more specifically. A recent study about molecular MRD in AML showed that the detection of molecular MRD is associated with a significantly higher relapse rate (51). During the complete remission, persistent mutations associated with clonal hematopoiesis (*DNMT3A*, *TET2*, and *ASXL1* referred as *DTA* mutations) and non-*DTA* mutations can be detected by NGS. While *DTA* mutations do not have prognostic value for MRD, non-*DTA* mutations (such as mutations in *TP53*, *IDH1*, *IDH2* and genes related to the *Ras* pathway) with a higher allele frequency can predict relapse rates (51,52).

Among AML with myelodysplasia-related changes (AML-MRC) and therapy-related AML (t-AML), mutations in splicing factors genes such as *SRSF2*, *SF3B1*, *U2AF1*, *ZRSR2*, mutations on chromatin/histone modifications like *ASXL1*, *EZH2*, *BCOR*, *STAG2*, and *TP53* mutations are common (53). *NPM1* mutations in the absence of *FLT3-ITD* and double *CEBPA* mutations are fairly uncommon in AML-MRC and are associated with favorable overall survival. Patients in this category with *TP53* mutations had a poor prognosis regardless of age (46,54-56). After treating patients with alkylating agents/ionizing radiation, patients often have increased blasts with associated multilineage dysplasia that cause similar mutation profiles like in AML-MRC. Mutations of *TP53* can be seen in as many as 50% of t-AML cases with worse survival (11,53,57,58). Following a topoisomerase II inhibitor therapy, 20 to 30% of patients develop overt acute leukemia without a preceding myelodysplastic phase. These patients often show balanced chromosomal translocations involving 11q23 (*KMT2A/MLL*) or 21q22 (*RUNX1*) and are associated with monoblastic or myelomonocytic morphology (11,53,59,60). Mutations in *TP53*, *TET2*, and *PTPN11* (protein tyrosine phosphatase, non-receptor type 11), *IDH1/2*, *NRAS* are frequent in t-AML, but *FLT3* and *NPM1* mutations are less frequent than de novo AML (58,61).

Mutation profiles in Myelodysplastic Syndrome

Approximately half of the myelodysplastic syndrome is associated with recurrent cytogenetic abnormalities such as -5/del(5q), -7/del(7q), +8del(20q) or complex karyotypes (62). Targeted panels and whole-genome NGS assay detect somatic mutations in up to 90% of MDS patients (63-65). Some of the mutations overlap with those observed in AML, none of these mutations are specific for MDS diagnosis. However, having multiple genetic abnormalities with high variant allele frequency is starting to be recognized for its supportive evidence of evolving MDS (66).

The most frequently mutated genes in MDS are *SF3B1* (~25%), *TET2* (~25%-20%), *ASXL1* (~15%), *SRSF2* (~15%), *RUNX1* (~15%-10%), *DNMT3A* (~15%-10%) (23). Mutations in *ASXL1*, *TP53*, *EZH2*, *ETV6*, and *RUNX1* are also found to be recurrent in MDS patients and predict a poor overall survival (41). *DNMT3A* mutations occur early in the course of MDS and suggest an early genetic event in leukemogenesis. Patients with *DNMT3A* mutations have a worse overall survival and more rapid progression to AML. They are associated with mutations in *FLT3* (ITD or TKD), *NPM1*, *IDH1* genes (67).

TP53 mutations in MDS are associated with the very aggressive disease. Even in low-risk MDS with del(5q), the presence of a *TP53* mutation at low frequency is correlated with a higher rate of leukemic transformation and poor response to lenalidomide (11,68).

Mutations in splicing factors are commonly detected in MDS patients with a frequency of 50%. The most common of these mutations are *SF3B1*, *SRSF2*, *U2AF1*, and *ZSR2* mutations. *SF3B1* mutations are the most common among splicing mutations in MDS. These mutations are highly correlated with the presence of ring sideroblast (RS). They are observed in 20% to 28% of MDS, more frequent in MDS with RSS and the frequency of *SF3B1* mutation in AML is <5% (11,23,69-71). Mutations in Cohesin Complex genes (*SMC1*, *SMC3*, *SCCI/RAD*, *STAG2*) can be germline resulting in Congenital Malformation syndrome. These mutations can be detected in 10% to 25% of MDS and 10% to 15% of *de novo* AML (17,69).

Nearly all cases of MDS show at least one mutation and demonstrate that specific mutation with a targeted NGS panel is highly useful for the diagnosis of MDS. However, determination of mutational burden/variant allele frequency (VAF) (usually >25% for MDS) is critical for the diagnostic assessment to distinguish MDS from clonal hematopoiesis of indeterminate potential (CHIP) or clonal cytopenia of undetermined significance (CCUS). CHIP is the proposed term for healthy individuals, lacking hematological malignancy or clonal disorder, but carrying a hematological somatic mutation. Key findings in CHIP are single gene mutations (mostly *DNMT3A*, *TET2* or *ASXL1* mutation), increased risk of developing hematological malignancy, and increased rate of cardiovascular mortality regardless of their cancer risk. The single mutation burden in CHIP has a VAF more than 2% but typically not exceeding 20%-30%, which allows the distinction from underlying dysplastic process (3). Patients who are not meeting the WHO defined criteria for a hematologic neoplasm, but show a clonal mutation with unexplained cytopenia, are referred to as CCUS. The mutation spectrum of CCUS patients is similar to mutations seen in MDS. Mutations in spliceosome genes (*SF3B1*, *SRSF2*, *U2AF1*, *ZSR2*) have the highest predictive value for CCUS (72). Co-mutations of *DNMT3A*, *TET2*, and *ASXL1* genes remain also common in CCUS. There are no clear recommendations to follow up CCUS patients. However, cytopenia, mutation burden, number and type of the mutations or the detection of additional mutations in the follow-up of a patient with suspected MDS appear to have a course similar to MDS (72-76).

Mutation profiles in myeloproliferative and myelodysplastic/myeloproliferative neoplasms

Disorders altering the myeloid elements include the following disorders: Polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), chronic myelogenous leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic leukemia/CEL, CMML, and mast cell disease. Among CMPD (PV, ET, PMF, and CML),

molecular markers have been essential for diagnosis. Recurrent somatic mutations in *BCR-ABL2* negative MPNs and MDS/MPNs are listed in Table 2.

The most frequent mutation in *BCR-ABL2* negative MPN, *JAK2* exon 14 (V617F) mutations are observed in 95% of PV patients (77). The majority of remaining PV patients may harbor a mutation in *JAK2* exon 12 (missense mutation, deletion, insertion). *JAK2* (V617F) mutation occurs in approximately 50-60% of ET or PMF patients. Homozygous mutations of *JAK2* (V617F) (with a VAF value >50%) are more common in PV than in ET (78,79). *JAK2* (V617F) mutation may not be present in half of the MPN patients. This type of mutation has rarely been reported in patients with MDS/MPN; however, they are found in patients with MDS, CMML, atypical CML, and *de novo* AML (approx. <5%) and MDS/MPN-RS-T (approx. 50%). In PV and ET, *JAK2* (V617F) allele burden is also associated with a more aggressive behavior. Thrombotic events and fibrotic transformation are more common in patients

with a high *JAK2* (V617F) allele burden (higher *JAK2* VAF). These findings suggest that monitoring *JAK2* (V617F) allele burden could be useful to identify patients at higher risk of myelofibrotic transformation. *JAK2* mutation in PMF is associated with intermediate prognosis when compared with *CALR* mutation (3,11,17,23,80).

Patients with ET have mutations in the *CALR* gene that encodes the endoplasmic reticulum and are associated with chaperone calreticulin at a frequency of 20% to 25%. *CALR* mutations are frequently seen in ET and PMF patients with *JAK2*^{wild} and *MPL*^{wild} type. They are rarely detected in PV, CMML, MDS/MPN patients. *CALR* mutations are not seen in AML, mastocytosis, lymphoid neoplasia and solid tumors (81,82). *CALR* mutated MPNs demonstrate distinct features; such as younger age group, lower hemoglobin levels, higher platelet counts, decreased risk of thrombosis, and improved overall survival compared to patients with *JAK2* or *MPL* mutations (83,84). In ET and PMF patients, *CALR* show 2 different mutations: type-I that typically has 52-bp deletion (p.L367fs*46), and type-II characterized by 5-bp

TABLE 2. Common gene mutations in MPN, MDS/MPN, and their clinical significance

Gene	Locus	Functional classification	Approx. frequency in MPN %			Approx. frequency in MDS/MPN %	Clinical significance
			PV	ET	PMF		
<i>JAK2</i>	9p24.1	Signal transduction	95	50-60	50-60	<1	Intermediate prognosis and a higher risk of thrombosis compared to patients with <i>CALR</i> mutation
<i>CALR</i>	13q12.2	Signal transduction	<1	20-25	20-30	2-6	Associated with better overall survival than <i>JAK2</i> V617F or <i>MPL</i> mutation (especially for type I/type 1-like mutation). Lower risk of thrombosis compared to <i>JAK2</i> mutation
<i>MPL</i>	19q13.11	Transcription factor mutation	<1	5-10	5-10	<2	Intermediate prognosis increased risk for thrombosis compared <i>JAK2</i> and <i>CALR</i> mutation
<i>SF3B1</i>	2q33.1	RNA splicing	1	1	5-10	20-30 (70-90 in MD/MPN-RS-T)	The presence of at least 1 of these “adverse variants/mutations” is associated with inferior overall survival, independent of age and karyotype
<i>TP53</i>	17p13.1	Tumor suppressor DNA repair	<1	<1	2-4	7-12	Associated with inferior leukemia-free survival in multivariate analysis
<i>DNMT3A</i>	2p23	DNA methylation	5-10	1-5	5-12	<5	Might be associated with adverse outcome and greater risk for AML transformation
<i>CBL</i>	4q24	DNA methylation	<1	0-2	5-10	40-60	Might be involved in leukemic transformation
<i>IDH</i>	2q34 (IDH1) 15q26.1 (IDH2)	DNA methylation	<2	<1	3-5	<10	The presence of at least 1 of these “adverse variants/mutations” is associated with inferior overall survival
<i>ASXL1</i>	20q11	Chromatin-Histone modification	2-7	5-10	15-35	40-50	The presence of at least 1 of these “adverse variants/mutations” is associated with inferior overall survival
<i>EZH2</i>	7q35-7q36	Chromatin-Histone modification	2	2	5-10	6-20	The presence of at least 1 of these “adverse variants/mutations” is associated with inferior overall survival
<i>SRSF2</i>	17q25.1	RNA splicing				35-50	The presence of at least 1 of these “adverse variants/mutations” is associated with inferior overall survival

AML: acute myeloid leukemia; ET: essential thrombocythemia; MD: myelodysplastic; MDS: myelodysplastic syndrome; MPN: myeloproliferative neoplasm; PMF: primary myelofibrosis; PV: polycythemia vera; RS-T: ring sideroblasts and thrombocytosis

TTGTC insertion (p.K385fs*47). Type I *CALR* mutation is detected more frequently in PMF than ET. Type II *CALR* mutations tend to show leukemic transformation (namely increased leucocyte count and higher circulating blasts) than type I *CALR* mutation (81,85,86). Platelet count is significantly higher in type II vs type I *CALR^{mut}* ET patients, but no difference was noted in thrombosis-free survival in a study with a large cohort of ET patients. However, there is a significant survival difference in the setting of PMF, as *CALR* type-I positive PMF patients do much better than *CALR* type-II or *JAK2* (V617F) positive PMF patients (84).

The activating mutation on codon W515 of *MPL* gene is seen in 5-10% of ET and PMF patients who are negative for *JAK2* (V617F) (87). Patients that are *JAK2^{wild}* and *CALR^{wild}*, but harboring ET or PMF clinical features should be screened for *MPL* mutation. *MPL* mutated patients have increased the risk for thrombotic episodes and transfusion requirement compared with *JAK2^{mut}* and *CALR^{mut}* patients (80,88,89). Patients with PMF have mutations for *JAK2* in 60%, *CALR* in 20-30% and *MPL* in 5-10% of the cases (Figure 3). The remaining 10% to 15% of patients with ET or PMF patients have none of the above-mutated genes and these are named “triple negative” (85,90,91). This is a heterogeneous category and some of the ET patients may have rare non-canonical mutations in *JAK2*, *MPL*, and *SH2B3*; however, the large majority remain without a specific mutation. For “triple negative” PMF patients, a detailed search for the mutation profiles regarded as a marker of clonality (such as *ASXL1*, *EZH2*, *TET2*, *IDH1*/*IDH2*, *SRSF2*, *SF3B1*) is currently recommended (77). “Triple negative” patients tend to show inferior outcome compared to *JAK2^{mut}*/*CALR^{mut}* and *MPL^{mut}* CMPD patients. The presence of at least one of the 3 variants/mutations (*ASXL1*, *SRSF2*, and *IDH2*) is associated with inferior overall and myelofibrosis-free survival in patients with PV. *SH2B3*, *IDH2*, *U2AF1*, *SF3B1*, *EZH2*, and *TP53* mutations are identified as significant risk factors for inferior overall, myelofibrosis-free survival, and leukemia-free survival in patients with ET (85).

Recent studies about leukemic transformation in MPNs show *ASXL1*, *SRSF2*, *IDH1*, *IDH2*, *RUNX1* mutations have been associated with leukemic transformation in PMF, whereas *SRSF2*, *IDH2* mutations in PV and *TP53*, *EZH2* mutations in

ET predicts more leukemic transformation (92). These findings show that the mutation spectrum in primary NK-AML is different from secondary AML. Recurrent somatic gene mutations are observed in up to 90% of CMML patients. *TET2* (~60%), *SRSF2* (~50%), *ASXL1* (~50%), *RUX1*, *NRAS*, and *TP53* are the most frequent mutations. However, these mutations can also be encountered in healthy aging people such as CHIP with a single mutation of a VAF <20-30%. Therefore, a low VAF of these mutations should not be used as a definitive diagnosis for CMML (23). *ASXL1* mutations are associated with a higher white blood cell count, lower hemoglobin, extramedullary disease, and an abnormal karyotype. *ASXL1* mutations lead to the aggressive clinical course in CMML patients (93,94). The *JAK2* mutation also occurs in CMML patients sharing some mutual features with *JAK2^{mut}* MPNs. These cases predict more reticulin fibrosis, occasional megakaryocytic clustering with atypia, and erythroid and megakaryocytic hyperplasia (95). In case of presence, *NPM1^{mut}* AML with monocytic differentiation should be suspected. Variable results are also expected on *JAK^{mut}* CMML patients treated with *JAK2* inhibitors (11,96,97). Juvenile myelomonocytic leukemia (JMML) patients harbor also clonal cytogenetic abnormalities. The commonly mutated genes are *KRAS/NRAS*, *NF1*, *PTPN11*, *CBL*, which encode proteins of the Ras oncogene pathway. *PTPN11* mutations are the most frequent alterations (~35%). Somatic *NRAS* and *KRAS* mutations occur in 20-25% of JMML cases. Germline mutations in *CBL* and *NF1* genes are also frequent and are associated with Noonan Syndrome-like disorder and neurofibromatosis type-I on JMML patients, respectively (98,99).

SETBP1 and ethanolamine kinase 1 (*ETNK1*) mutations are relatively common in atypical CML (aCML). *CSF3R* mutation is frequently associated with CNL, this type of mutation is uncommon (<10%) in aCML and rarely encountered in CMML and AML cases (100,101). Correlation of *CSF3R* mutation with CNL has been included in the diagnostic criteria in the revised 2016 WHO classification (10,21). In myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T), *SF3B1* mutations are present in 70-90% of cases. They are frequently commutated with *JAK2* (V617F) (50-65%) and less frequently with *CALR/MPL* (11,23,70,71).




FIG. 3. Distribution of mutation profiles in myeloproliferative neoplasm.
ET: essential thrombocythemia; PMF: primary myelofibrosis; PV: polycythemia vera

Among myeloid neoplasms with eosinophilia; CEL-NOS, idiopathic hypereosinophilic syndrome, myeloid/lymphoid neoplasms with eosinophilia, and gene rearrangement are considered in the revised 2016 WHO classification. However, hypereosinophilia can be encountered in systemic mastocytosis, CML, other types of MPNs, MDS/MPNs, AML, MDS and T cell lymphoproliferative disorders. Once, cytogenetically *PDGFRA*, *PDGFRB*, *FGFR1* rearrangements, and *PCMT-JAK2* fusion and other causes of hypereosinophilia are excluded, NGS should be performed for the patients with eosinophilia.

Lastly, mast cell diseases show point mutations of the *KIT* gene (D816V) in 95% of cases. Although the presence of D816V mutations is important at diagnosis for systemic mastocytosis, a minority of patients harbor mutations on exon 17 or other exons (102). Additionally; *TET2*, *ASXL1*, *RUX1*, *SRSF2*, and *JAK2* mutations can be seen on the patients with mastocytosis (103,104).

We outlined some of the common genes that are important to assess in various hematologic neoplasms with emphasis on myeloid neoplasia. Despite the significant progress in lymphoid neoplasms, particularly for understanding its pathogenesis, NGS is no ready to be integrated into routine clinical testing. Most of the NGS panels offered for assessment of myeloid neoplasms contain between 30-60 targeted genes. The market for NGS-based diagnostic procedures is rapidly growing, therefore it is impossible to list all the available tests. However, based on current literature, a panel with the following genes will most likely be informative in clinical assessment for most of the myeloid neoplasms: *FLT3*, *NPM1*, *CEBPA*, *TP53*, *IDH1/2*, *DNMT3A*, *TET2*, *CSF3R*, *SRSF2*, *KIT*, *NRAS*, *RUNX1*, *WT1*, *ASXL1*, *SF3B1* for AML; *NRAS*, *KRAS*, *IDH1/2*, *TET2*, *EZH2*, *ASXL1*, *RUNX1*, *TP53*, *DNMT3A*, *SF3B1*, *U2AF1*, *ETV6* for MDS; *JAK2*, *CALR*, *MPL*, *IDH1/2*, *ASXL1*, *TET2*, *EZH2*, *SRSF2*, *SF3B1*, *TP53* for MPN; *TET2*, *SRSF2*, *ASXL1*, *RUNX1*, *NRAS*, *TP53* for CMML; *SF3B1* for MD/MPN RS-T; *CSF3R* for CNL, *SETBP1* for aCML, *KIT* (D816V) for mast cell disease.

In conclusion; the progress of NGS and widen utilization on hematologic malignancies will facilitate a more precise diagnosis and treatment for patients with hematologic neoplasms. AML, MDS, and MPNs are characterized by morphologic or phenotypic similarities but these disorders harbor different mutations types with different prognostic implications. Myeloid neoplasms that lack a cytogenetic alteration but show a somatic mutation can be diagnosed by the above-mentioned mutation profiles. These mutations can also facilitate new novel therapeutic agents. In the coming years, it appears that major efforts with more comprehensive high throughput NGS sequencing and inclusion of genomic data in clinical management will enable the delivery of precision medicine.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: No financial disclosure was declared by the authors.

REFERENCES

1. Kuo FC. Next generation sequencing in hematolymphoid neoplasia. Seminars in Hematology 2018.
2. Yohe S, Thyagarajan B. Review of Clinical Next-Generation Sequencing. Arch Pathol Lab Med 2017;141:1544-57.
3. Sallman DA, Padron E. Integrating mutation variant allele frequency into clinical practice in myeloid malignancies. Hematol Oncol Stem Cell Ther 2016;9:89-95.
4. Jaffe E AD, Campo E, Harris NL, Quintanilla-Martinez L. Hematopathology Molecular Diagnosis in Hematopathology. Molecular Diagnosis in Hematopathology. Philadelphia PA: Elsevier; 2017:1-1216.
5. Cancer Genome Atlas Research Network, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013;368:2059-74.
6. Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007;109:431-48.
7. Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med 2015;373:1136-52.
8. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391-405.
9. Duncavage EJ, Tandon B. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes. Int J Lab Hematol 2015;37(Suppl 1):115-21.
10. Sperling AS, Gibson CJ, Ebert BL. The genetics of myelodysplastic syndrome: from clonal hematopoiesis to secondary leukaemia. Nat Rev Cancer 2017;17:5-19.
11. Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues 2017.
12. Dang L, Jin S, Su SM. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med 2010;16:387-97.
13. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254-66.
14. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010;363:2424-33.
15. Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: Prognostic and therapeutic implications. J Clin Oncol 2011;29:475-86.
16. Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H, et al. *TET2* mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: A cancer and leukemia group B study. J Clin Oncol 2011;29:1373-81.
17. Patel U, Luthra R, Medeiros LJ, Patel KP. Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms. Clin Lymphoma Myeloma Leuk 2017;17:62-74.
18. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, Bullinger L, et al. *IDH1* and *IDH2* mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with *NPM1* mutation without *FLT3* internal tandem duplication. J Clin Oncol 2010;28:3636-43.
19. Chang C-C OR. Precision Molecular Pathology of Myeloid Neoplasms. In: PT C, editor. Precision Molecular Pathology of Myeloid Neoplasms. Acute Myeloid Leukemia with Recurrent Genetic Abnormalities, Part II: Mutations Involving *CEBPA*, *NPM1*, and *RUNX1*: Springer International Publishing AG; 2018:427.
20. Perl AE. The role of targeted therapy in the management of patients with AML. Hematology Am Soc Hematol Educ Program 2017;2017:54-65.
21. DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable Remissions with Ivosidenib in *IDH1*-Mutated Relapsed or Refractory AML. N Engl J Med 2018;378:2386-98.
22. Bains A, Luthra R, Medeiros LJ, Zuo Z. *FLT3* and *NPM1* mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia. Am J Clin Pathol 2011;135:62-9.
23. E. H. Hematopathology: A Volume in the Series: Foundations in Diagnostic Pathology. In: JR G, editor. Hematopathology. Molecular Hematopathology. 3rd ed. Philadelphia, PA: Elsevier; 2018:800.
24. Mendler JH, Maharry K, Radmacher MD, Mrozek K, Becker H, Metzeler KH, et al. *RUNX1* mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. J Clin Oncol 2012;30:3109-18.

25. Gaidzik VI, Bullinger L, Schlenk RF, Zimmermann AS, Röck J, Paschka P, et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. *J Clin Oncol* 2011;29:1364-72.
26. Kussick SJ, Stirewalt DL, Yi HS, Sheets KM, Pogosova-Agadjanyan E, Braswell S, et al. A distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication. *Leukemia* 2004;18:1591-8.
27. O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, et al. Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2017;15:926-57.
28. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. *N Engl J Med* 2017;377:454-64.
29. Assi R, Ravandi F. FLT3 inhibitors in acute myeloid leukemia: Choosing the best when the optimal does not exist. *Am J Hematol* 2018;93:553-63.
30. Kayser S, Levis MJ. FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations. *Leuk Lymphoma* 2014;55:243-55.
31. Nardi V, Hasserjian RP. Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. *Surg Pathol Clin* 2016;9:143-63.
32. Kiyoi H, Naoe T. FLT3 mutations in acute myeloid leukemia. *Methods Mol Med* 2006;125:189-97.
33. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. *N Engl J Med* 2016;374:2209-21.
34. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. *N Engl J Med* 2012;366:1079-89.
35. Allen C, Hills RK, Lamb K, Evans C, Tinsley S, Sellar R, et al. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. *Leukemia* 2013;27:1891-901.
36. Boissel N, Leroy H, Brethon B, Philippe N, de Botton S, Auvrignon A, et al. Incidence and prognostic impact of c-KIT, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). *Leukemia* 2006;20:965-70.
37. Balsat M, Renneville A, Thomas X, de Botton S, Caillot D, Marceau A, et al. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. *J Clin Oncol* 2017;35:185-93.
38. Bejar R, Lord A, Stevenson K, Bar-Natan M, Pérez-Ladaga A, Zaneveld J. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. *Blood* 2014;124:2705-12.
39. Medeiros BC, Fathi AT, DiNardo CD, Polleyea DA, Chan SM, Swords R. Isocitrate dehydrogenase mutations in myeloid malignancies. *Leukemia* 2017;31:272-81.
40. Patnaik MM, Hanson CA, Hodnefield JM, Lasho TL, Finke CM, Knudson RA, et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: A Mayo Clinic Study of 277 patients. *Leukemia* 2012;26:101-5.
41. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. *N Engl J Med* 2011;364:2496-506.
42. Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. *J Hematol Oncol* 2012;5:12.
43. Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. *Br J Haematol* 2009;145:788-800.
44. Bacher U, Haferlach T, Kern W, Haferlach C, Schnittger S. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. *Haematologica* 2007;92:744-52.
45. Sun QY, Ding LW, Tan KT, Chien W, Mayakonda A, Lin DC, et al. Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD). *Leukemia* 2017;31:1-10.
46. Devillier R, Mansat-De Mas V, Gelsi-Boyer V, Demur C, Murati A, Corre J, et al. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. *Oncotarget* 2015;6:8388-96.
47. Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. *Blood* 2015;125:1367-76.
48. Rucker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. *Blood* 2012;119:2114-21.
49. Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. *N Engl J Med* 2016;375:2023-36.
50. Welch JS, Petti AA, Ley TJ. Decitabine in TP53-Mutated AML. *N Engl J Med* 2017;376:797-8.
51. Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, et al. Molecular Minimal Residual Disease in Acute Myeloid Leukemia. *N Engl J Med* 2018;378:1189-99.
52. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood* 2017;129:424-47.
53. Li P. ORS. Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Therapy-Related Myeloid Neoplasms, and Acute Myeloid Leukemia, Not Otherwise Specified. In: Chang CC, Ohgami R, editors. *Precision Molecular Pathology of Myeloid Neoplasms*. Springer, Cham; 2018.
54. Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Görlich D, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. *Blood* 2016;128:686-98.
55. Devillier R, Gelsi-Boyer V, Brecqueville M, Carbuccia N, Murati A, Vey N, et al. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations. *Am J Hematol* 2012;87:659-62.
56. Ohgami RS, Ma L, Merker JD, Gotlib JR, Schrijver I, Zehnder JL, et al. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. *Mod Pathol* 2015;28:706-14.
57. Bhatia S. Therapy-related myelodysplasia and acute myeloid leukemia. *Semin Oncol* 2013;40:666-75.
58. Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Fu B, Tang G, et al. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. *Leuk Res* 2015;39:348-54.
59. Arber DA, Slovak ML, Popplewell L, Bedell V, Ikle D, Rowley JD, et al. Therapy-related acute myeloid leukemia/myelodysplasia with balanced 21q22 translocations. *Am J Clin Pathol* 2002;117:306-13.
60. Czader M, Orazi A. Acute Myeloid Leukemia and Other Types of Disease Progression in Myeloproliferative Neoplasms. *Am J Clin Pathol* 2015;144:188-206.
61. Shih AH, Chung SS, Dolezal EK, Zhang SJ, Abdel-Wahab OI, Park CY, et al. Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. *Haematologica* 2013;98:908-12.
62. Tiu RV, Visconte V, Traina F, Schwandt A, Maciejewski JP. Updates in cytogenetics and molecular markers in MDS. *Curr Hematol Malig Rep* 2011;6:126-35.
63. Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. *Blood* 2007;110:4385-95.
64. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. *Leukemia* 2014;28:241-7.
65. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. *Blood* 2013;122:3616-27.
66. Bartels S, Schipper E, Hasemeier B, Kreipe H, Lehmann U. Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms. *Oncotarget* 2016;7:30084-93.
67. Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. *Leukemia* 2011;25:1153-8.
68. Jadersten M, Saft L, Smith A, Kulasekaran J, Pomplun S, Göhring G, et al. TP53 mutations in low-risk myelodysplastic syndromes with del (5q) predict disease progression. *J Clin Oncol* 2011;29:1971-9.

69. Kuo FC, Dong F. Next-generation sequencing-based panel testing for myeloid neoplasms. *Curr Hematol Malig Rep* 2015;10:104-11.
70. Papaemmanuil E, Cazzola M, Boulton J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. *N Engl J Med* 2011;365:1384-95.
71. Brecqueville M, Rey J, Bertucci F, Coppin E, Finetti P, Carbuccia N, et al. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. *Genes Chromosomes Cancer* 2012;51:743-55.
72. Malcovati L, Galli A, Travaglino E, Ambaglio I, Rizzo E, Molteni E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. *Blood* 2017;129:3371-8.
73. Jain M, Tripathi A. ICUS/CCUS/CHIP: basics & beyond. *Expert Rev Hematol* 2017;10:915-20.
74. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. *N Engl J Med* 2014;371:2488-98.
75. Zink F, Stacey SN, Nordahl GL, Frigge ML, Magnusson OT, Jonsdottir I, et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. *Blood* 2017;130:742-52.
76. Brauninger A, Blau W, Kunze K, Desch AK, Brobeil A, Tur MK, et al. Targeted Next-Generation Sequencing Is a Sensitive Tool for Differential Diagnosis of Myelodysplastic Syndromes in Bone Marrow Trephines. *J Mol Diagn* 2018;20:344-54.
77. Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. *Blood Cancer J* 2018;8:15.
78. Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY, et al. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. *Br J Haematol* 2005;131:320-8.
79. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. *Lancet* 2005;365:1054-61.
80. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. *Blood* 2007;110:840-6.
81. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. *N Engl J Med* 2013;369:2379-90.
82. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. *N Engl J Med* 2013;369:2391-405.
83. Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. *Blood* 2014;123:1552-5.
84. Tefferi A, Lasho TL, Finke C, Belachew AA, Wassie EA, Ketterling RP, et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. *Leukemia* 2014;28:1568-70.
85. Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, et al. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. *J Natl Compr Canc Netw* 2017;15:1193-207.
86. Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. *Blood* 2014;124:2507-13.
87. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. *PLoS Med* 2006;3:270.
88. Langabeer SE, Andrikovics H, Asp J, Bellosillo B, Carillo S, Haslam K, et al. Molecular diagnostics of myeloproliferative neoplasms. *Eur J Haematol* 2015;95:270-9.
89. Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillo A, Casetti I, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. *Blood* 2014;124:1062-9.
90. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. *Leukemia* 2010;24:1128-38.
91. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. *J Clin Oncol* 2011;29:573-82.
92. Yogarajah M, Tefferi A. Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome. *Mayo Clin Proc* 2017;92:1118-28.
93. Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. *J Clin Oncol* 2013;31:2428-36.
94. Wassie EA, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study. *Am J Hematol* 2014;89:1111-5.
95. Pich A, Riera L, Sismondi F, Godio L, Davico Bonino L, Marmont F, et al. JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. *J Clin Pathol* 2009;62:798-801.
96. Padron E, Dezern A, Andrade-Campos M, Vaddi K, Scherle P, Zhang Q, et al. A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). *Clin Cancer Res* 2016;22:3746-54.
97. E.D. GMH. Chronic Myelomonocytic Leukemia: Clinical and Pathologic Features. In: Chung-Che (Jeff) Chang RSO, editor. Precision Molecular Pathology of Myeloid Neoplasms. VOL 12: Springer International Publishing AG 2018:2018.
98. Caye A, Strullu M, Guidez F, Cassinat B, Gazal S, Fenneteau O, et al. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. *Nat Genet* 2015;47:1334-40.
99. Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. *Nat Genet* 2010;42:794-800.
100. Gambacorti-Passerini CB, Donadoni C, Parmiani A, Pirola A, Redaelli S, Signore G, et al. Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. *Blood* 2015;125:499-503.
101. Meggendorfer M, Bacher U, Alpermann T, Haferlach C, Kern W, Gambacorti-Passerini C, et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. *Leukemia* 2013;27:1852-60.
102. Wang SA, Tam W, Tsai AG, Arber DA, Hasserjian RP, Geyer JT, et al. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. *Mod Pathol* 2016;29:854-64.
103. Arock M, Sotlar K, Akin C, Broesby-Olsen S, Hoermann G, Escribano L, et al. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. *Leukemia* 2015;29:1223-32.
104. Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. *Blood* 2013;122:2460-6.